By Nana O 
Researchers at Washington University School of Medicine in St. Louis, collaborating with scientists at Northwestern University, have unveiled a revolutionary noninvasive strategy poised to transform the treatment landscape for glioblastoma, one of the most aggressive and deadly forms of brain cancer. This pioneering method harnesses the power of precisely engineered nanostructures, tiny materials capable of delivering potent cancer-fighting compounds directly into the brain via simple nasal drops. In preclinical studies utilizing mice, this innovative approach demonstrated remarkable success in treating glioblastoma by effectively stimulating the brain’s own immune system, a significant advancement that sidesteps the inherent invasiveness of many existing and emerging therapeutic techniques. The findings, published this month in the prestigious journal Proceedings of the National Academy of Sciences (PNAS), represent a critical step forward in the quest for more effective and patient-friendly cancer therapies.
The Persistent Challenge of Glioblastoma
Glioblastoma multiforme (GBM) originates from astrocytes, glial cells that provide support and insulation for neurons in the brain. It stands as the most prevalent and aggressive malignant primary brain tumor in adults, affecting approximately three in every 100,000 individuals in the United States annually. The disease is characterized by its rapid growth and invariably poor prognosis, with median survival rates often measured in months, even with aggressive treatment regimens. A primary impediment to successful treatment has historically been the formidable challenge of delivering therapeutic agents across the blood-brain barrier (BBB), a highly selective biological shield that protects the brain from pathogens and toxins but also severely restricts the passage of many vital medications. This inherent difficulty has fueled a desperate search for alternative delivery mechanisms and treatment modalities.
"Our goal was to fundamentally alter this grim reality by developing a noninvasive treatment that could effectively mobilize the immune system to combat glioblastoma," stated Alexander H. Stegh, PhD, a professor and vice chair of research in the WashU Medicine Taylor Family Department of Neurosurgery and a co-corresponding author of the study. Dr. Stegh, who also holds the esteemed position of research director at The Brain Tumor Center at Siteman Cancer Center, a collaborative effort between Barnes-Jewish Hospital and WashU Medicine, elaborated on the significance of their findings. "Through this research, we have demonstrated that meticulously designed nanostructures, known as spherical nucleic acids (SNAs), possess the capability to safely and effectively activate potent immune pathways within the brain. This breakthrough fundamentally redefines the potential for cancer immunotherapy in tumors that have historically been exceedingly difficult to access and treat."
Reactivating the Immune System: The STING Pathway as a Key Target
Glioblastoma is notoriously characterized as a "cold tumor" by oncologists and immunologists. This designation signifies its inherent ability to evade detection and destruction by the immune system, lacking the molecular signals that typically attract immune cells to a site of malignancy. In stark contrast to "hot tumors," which are more amenable to current immunotherapies due to their robust inflammatory microenvironment, glioblastoma actively suppresses immune responses. A significant area of research focus has been the exploration of pathways that can overcome this immune evasion, with the STING (stimulator of interferon genes) pathway emerging as a particularly promising target. The STING pathway is a critical component of the innate immune system, designed to detect the presence of foreign DNA, such as that found in viral or bacterial invaders, and subsequently initiate a cascade of immune defenses.
Previous investigations had established that drugs capable of activating the STING pathway could prime the immune system to recognize and attack glioblastoma cells. However, these promising compounds suffered from significant limitations: they were prone to rapid degradation in the body and, crucially, required direct injection into the tumor to achieve therapeutic concentrations. Given that glioblastoma often necessitates multiple treatment rounds, this approach translated into a series of highly invasive surgical procedures, posing substantial risks and burdens for already vulnerable patients.
"We were acutely aware of the significant burden that invasive procedures place on patients battling serious illnesses, and we were determined to find a less arduous alternative," explained Akanksha Mahajan, PhD, a postdoctoral research associate in Dr. Stegh’s laboratory and the first author of the study. "My hypothesis was that we could leverage the unique properties of spherical nucleic acid platforms to deliver these STING-activating drugs in a completely noninvasive manner."
The Architecture of Hope: Gold-Core Nanostructures for Nose-to-Brain Delivery
To translate this ambitious vision into a tangible therapy, Dr. Stegh’s team forged a crucial partnership with Chad A. Mirkin, PhD, a leading figure in nanotechnology and the director of the International Institute for Nanotechnology and the Rathmann Professor of Chemistry at Northwestern University. Professor Mirkin is renowned for his pioneering work in the development of spherical nucleic acids (SNAs). These sophisticated nanostructures are characterized by their dense coating of DNA or RNA molecules arranged around a core, a configuration that has been shown to significantly enhance their stability and cellular uptake compared to conventional delivery systems.
The collaborative effort between the Washington University and Northwestern teams focused on designing a specialized iteration of SNAs. These novel nanostructures featured a core composed of gold nanoparticles, chosen for their biocompatibility and well-established utility in nanomedicine, meticulously coated with short DNA fragments engineered to specifically activate the STING pathway within targeted immune cells. The critical innovation lay in the chosen route of administration: the nasal passages. Intranasal delivery has been explored previously for its potential to bypass the blood-brain barrier and deliver therapeutics directly to the brain, but until this research, no nanoscale therapy had successfully demonstrated the ability to elicit a robust immune response against brain tumors via this route.
"This represents a landmark achievement, as it is the first documented instance where nanoscale therapeutics delivered intranasally have successfully enhanced immune cell activation within glioblastoma tumors," Mahajan emphasized, highlighting the novel nature of their findings.
Tracing the Nanodrops: A Journey to the Brain and Beyond
A key objective of the research was to definitively prove both the selective delivery of the nanostructures to the brain and their efficacy in activating the intended immune cells. To achieve this, the researchers incorporated a molecular tag into the spherical nucleic acids that emitted a fluorescent signal detectable under near-infrared light. Following the administration of these "nanodrops" to mice that had been induced with glioblastoma, the research team meticulously tracked the particles’ journey. Their observations confirmed that the nanostructures traveled along the olfactory nerve pathway, a well-established route connecting the nasal cavity to various regions of the brain.
Upon reaching their target, the immune response triggered by the nanomedicine was found to be concentrated within specific immune cells residing in and around the tumor microenvironment. Furthermore, a measurable level of immune activation was also detected in nearby lymph nodes, indicating a systemic engagement of the immune system. Crucially, the study revealed that the therapy did not disseminate widely throughout the body, a factor that significantly mitigates concerns about potential off-target effects and systemic toxicity, thereby enhancing the safety profile of the treatment.
Subsequent detailed histological and molecular analyses confirmed that key immune cells within and adjacent to the tumor had indeed activated the STING pathway. This activation conferred upon these cells a heightened capacity to recognize and mount a more aggressive attack against the glioblastoma cells, effectively turning the body’s own defenses against the cancer.
Synergistic Strategies: Eradicating Tumors and Forging Lasting Immunity
The therapeutic potential of this nanotherapy was further amplified when it was combined with established immunomodulatory agents designed to activate T lymphocytes, another critical class of immune cells that play a central role in adaptive immunity. This two-pronged approach, involving the STING-activating nanodrops followed by T cell-activating medication, resulted in the complete eradication of tumors in the mouse models. Remarkably, this aggressive treatment also induced a durable, long-lasting immune memory, effectively preventing the recurrence of the cancer. These outcomes represented a significant improvement over the efficacy observed with current experimental STING-targeting therapies, underscoring the superior performance of this novel nanodelivery system.
Dr. Stegh cautioned that while stimulating the STING pathway is a powerful strategy, it is unlikely to be a standalone cure for glioblastoma. He explained that the tumor has evolved a sophisticated repertoire of mechanisms to dampen or completely shut down immune responses. To address this, his team is actively investigating strategies to incorporate additional immune-activating functionalities directly into the nanostructure design. This approach could enable a single, unified treatment to simultaneously target multiple pathways that contribute to immune resistance, offering a more comprehensive and potent therapeutic intervention.
"This represents a paradigm shift in how we can approach glioblastoma and potentially other cancers that are resistant to current immunotherapies," Dr. Stegh asserted, expressing optimism for the future. "It is an approach that offers genuine hope for developing safer, more effective treatments, and it marks a critical milestone on the path toward clinical translation and ultimately, benefiting patients."
Funding and Disclosure: A Collaborative Effort
This groundbreaking research was made possible through substantial support from various national and institutional funding bodies. Key grants were provided by the National Cancer Institute of the National Institutes of Health (NIH) under grant numbers P50CA221747 and R01CA275430, and by the NIH with grants R01CA120813, R01NS120547, and R01CA272639. Additional support came from the Melanoma Research Foundation, the Chicago Cancer Baseball Charities at the Lurie Cancer Center of Northwestern University, and direct grants from Cellularity, Alnylam, and AbbVie. The advanced imaging capabilities at the Siteman Cancer Center Small Animal Cancer Imaging facility were supported by NIH instrumentation grants S10OD027042 and S10OD025264, and the National Cancer Institute Cancer Center grant P30CA091842. PET and MRI imaging services were also supported by the Robert H. Lurie Comprehensive Cancer Center Grant P30CA060553. The content of this publication is solely the responsibility of the authors and does not necessarily reflect the official views or policies of the NIH.
The researchers have disclosed potential conflicts of interest. Dr. Alexander Stegh is a shareholder in Exicure Inc., a company actively involved in the development of SNA therapeutic platforms. Professor Chad Mirkin is a shareholder in Flashpoint, a company developing SNA-based therapeutics. Both Dr. Stegh and Professor Mirkin are listed as co-inventors on patent US20150031745A1, which details the use of SNA nanoconjugates for crossing the blood-brain barrier. These disclosures are standard practice in scientific publishing to ensure transparency and allow readers to assess potential influences on the research findings.
